A study involving buserelin was published on June 30, 2026, in the Journal of Molecular Histology. The publication is titled "Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis." Buserelin remains an approved compound. This entry reflects the appearance of a new peer reviewed publication referencing buserelin in the scientific literature. No findings, outcomes, or comparative results from the study are detailed here beyond the published title itself. Readers seeking the full scope of the research, including methodology and reported results, should consult the original journal article directly through the linked source. This brief serves only to note that the publication exists and identifies its title, journal, and publication date as provided. For general background on buserelin, including its approved regulatory status and typical context of use, readers can refer to the compound overview.</body_markdown>
<parameter name="sources">["https://pubmed.ncbi.nlm.nih.gov/42380362/"]